The second newsletter of the PREDICTION-ADR consortium has been published. Read about the recent annual plenary meeting of the consortium held in Uppsala where the progress of the research was discussed. PREDICTION-ADR partner ASPER Biotech is now marketing a genetic test which can help predict which patients are likely to suffer adverse reactions to statins. PREDICTION-ADR research has revealed serious risks to patients of continuing ACE inhibitor therapy after suffering angioedema. A method to improve the efficiency of studies on ACEi induced angioedema using healthcare databases has been published. A further PREDICTION-ADR publication reports a gene variant which is associated with a common side effect of ACEi treatment. PREDICTION-ADR is also now collaborating with Danish researchers to reach a wider European population. Download Newsletter……
You may also like
Around 10% of individuals taking ACE inhibitors (ACEI) to control blood pressure will develop a persistent dry cough. This leads to inappropriate […]
The first newsletter of the PREDICTION-ADR consortium has been published. Read about the recent annual plenary meeting of the consortium held in […]
PREDICTION-ADR partner Asper Biotech is working on the implementation of new reliable and validated testing panels to predict the side effects of statins and ACE […]